Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | FPR2 | P25090 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.58 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.58 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.58 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8577834 | 0.90 | POLB (0.63) | SMN1; SMN2KMT2AGLAALDH1A1MEN1 | |
| SCHEMBL16562142 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL17919369 | 0.86 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL30858767 | 0.86 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL659053 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL5944191 | 0.84 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL12773610 | 0.84 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL4583404 | 0.84 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL4322629 | 0.84 | GLA (0.77) | SMN1; SMN2KMT2AGLATAAR1ALDH1A1 | |
| SCHEMBL8015010 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AGLAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| WO-2010039256-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| US-5719279-A | CHOLINOMIMETICS | BOEHRINGER INGELHEIM KG (DE) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | SMN1; SMN2 4830/4885KMT2A 3223/4885GLA 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.